Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diprosone OV ointment vasoconstriction dose-duration response study in healthy volunteers
ACTRN12623001181695Phase 4Completed
- Sponsor
- Zenith Technologies
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of betamethasone dipropionate in atopic dermatitis (AD) and psoriasis, sponsored by Zenith Technologies. Primary endpoints: ED50 parameter of Diprosone OV ointment and D1 parameter of Diprosone OV ointment. Started May 2024; status: completed.
02
Drugs
betamethasone dipropionate
03
Conditions
atopic dermatitis (AD)psoriasis
Beyond the preview
Go deeper on ACTRN12623001181695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623001181695.